Patents/Inventors

Martin E. Sanders

Spring, TXUS12 patents

13 Patents

US123835212025
Treatment of Diseases by Concurrently Eliciting Remyelination Effects and Immunomodulatory Effects Using Selective RXR Agonists
Trustees Of Dartmouth College
0 cites
US123256852025
RXR Agonist Salt Form, Polymorphs Thereof, and Uses Thereof
Io Therapeutics, Inc.
0 cites
US121151932024
Methods of Using Rarγ Agonists for Cancer Treatment
Io Therapeutics, Inc.
0 cites
US119985212024
Use of an RXR Agonist in Treating Drug Resistant HER2+ Cancers
Board Of Regents, The University Of Texas System
0 cites
US119198482024
RXR Agonist Salt Form, Polymorphs Thereof, and Uses Thereof
Io Therapeutics, Inc.
0 cites
US118965582024
Use of an RXR Agonist and Taxanes in Treating Her2+ Cancers
Board Of Regents, The University Of Texas System
0 cites
US117938352023
Methods of Using Rarγ Agonists for Cancer Treatment
Io Therapeutics, Inc.
0 cites
US117865552023
RAR Selective Agonists in Combination with Immune Modulators for Cancer Immunotherapy
Io Therapeutics, Inc.
0 cites
US117795582023
Receptor Subtype and Function Selective Retinoid and Rexinoid Compounds in Combination with Immune Modulators for Cancer Immunotherapy
Io Therapeutics, Inc.
0 cites
US117379962023
Immunomodulatory and Differentiating Function Selective Retinoid and Rexinoid Compounds in Combination with Immune Modulators for Cancer Immunotherapy
Io Therapeutics, Inc.
0 cites
US116908312023
Treatment of Autoimmune Diseases with Combinations of RXR Agonists and Thyroid Hormones
IO Therapeutics, Inc.
0 cites
US116908322023
Treatment of Autoimmune Diseases with Combinations of RXR Agonists and Thyroid Hormones
IO Therapeutics
0 cites
US116482232023
Receptor Subtype and Function Selective Retinoid and Rexinoid Compounds in Combination with Immune Modulators for Cancer Immunotherapy
Io Therapeutics, Inc.
0 cites